



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 66432

**Title:** Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03664977

**Position:** Editorial Board

**Academic degree:** FAASLD, MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Thailand

**Author's Country/Territory:** Pakistan

**Manuscript submission date:** 2021-03-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-29 01:57

**Reviewer performed review:** 2021-04-02 03:43

**Review time:** 4 Days and 1 Hour

<b>Scientific quality</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

### **SPECIFIC COMMENTS TO AUTHORS**

Apr2, 2021 Dear Editor WJH. Manuscript Title: Redefining NAFLD to MAFLD: Is this plausible? All Author List: Amna Subhan Butt, Aimun Subhan Raees and Jalpa Devi Comments: In this minireview, the authors highlight the key issues of why we need to change the terminology of NAFLD to MAFLD which enlightens the important of disease awareness of several stakeholders including patients, granting agency and health-care policy makers. I read this article with agreement in concept and will add minor revision as follows 1. Definition of NAFL in page 1 of <5% should be edited. 2.

Page2: thioglitazone should be specify to be Pioglitazone and should remove the metformin and probiotics from this sentence due to the lacking of evidence based to support. 3. Page3; - correct the small letter to capital letter of FIB-4- in line 5 from bottom 4. Page5; - correct and remove the phrase "can we write it" in line 5 from top 5.

Page5; - correct the small letter to capital letter of NAFLD- in line 8 from bottom



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 66432

**Title:** Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05917675

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** Pakistan

**Manuscript submission date:** 2021-03-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-03 22:17

**Reviewer performed review:** 2021-04-03 22:52

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

### **SPECIFIC COMMENTS TO AUTHORS**

Authors wrote an interesting review about a hot topic, however were minor concerns and the manuscript may be improved. 1. Please, rephrase " NAFLD: A lot has been done, Yet more required ", this type of title is more suited to an informative article than a scientific journal. 2. At page 1 Authors wrote [...] Various agents have been used in addition to lifestyle modification, ranging from thioglitazone, vitamin E (antioxidants), metformin to probiotics but none have proven to be useful while adverse effects and long-term safety remained a major concern[...].However, a recent article (doi:10.3390/nu12113379, PMID: 33153126) suggests that inositols, as Pinitol, reduce liver fat. Please, add these agents and update the reference in this section. 3. To support the definition of MAFLD in the appropriate paragraph ("The Rise of MAFLD") a recent study analysed the role of the metabolic syndrome and NAFLD on cardiovascular events in patients with atrial fibrillation. The study (doi: 10.1007/s11739-021-02682-3, PMID: 33713286) showed that the metabolic syndrome is a major cardiovascular risk factor than NAFLD, which could represent an epiphenomenon of the metabolic syndrome itself. 4. Please, move the text of "Author's two cents" to "Opinion versus evidence"